[Treatment of peritonitis during continuous ambulatory peritoneal dialysis (CAPD) with co-trimoxazole, cefazolin or vancomycin].
Three initial treatment schedules of peritonitis during continuous ambulatory peritoneal dialysis are analysed. In 20 patients 56 episodes of peritonitis were treated by co-trimoxazole, 29 episodes in 20 patients by cefazolin, and 29 infections in 22 patients by vancomycin. The efficiency of the treatment modes was comparable. Vancomycin was found to be appropriate in particular because of the resistance characteristics of bacterial isolates.
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001230:Aspergillus / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects; D002175:Candida / Q000187:drug effects; D002437:Cefazolin / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use*; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004338:Drug Combinations; D014640:Vancomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D002437:Cefazolin; D013420:Sulfamethoxazole
Behandlung der Peritonitis während kontinuierlich ambulanter Peritonealdialyse (CAPD) mit Co-Trimoxazol, Cefazolin oder Vancomycin.